O	0	13	Topoisomerase	Topoisomerase	NN	B-NP
O	14	15	I	I	CD	I-NP
O	16	23	protein	protein	NN	I-NP
O	24	34	expression	expression	NN	I-NP
O	35	37	in	in	IN	B-PP
B-Cancer	38	45	primary	primary	JJ	B-NP
I-Cancer	46	56	colorectal	colorectal	JJ	I-NP
I-Cancer	57	63	cancer	cancer	NN	I-NP
O	64	67	and	and	CC	I-NP
B-Cancer	68	73	lymph	lymph	NN	I-NP
I-Cancer	74	78	node	node	NN	I-NP
I-Cancer	79	89	metastases	metastasis	NNS	I-NP
O	89	90	.	.	.	O

O	92	105	Topoisomerase	Topoisomerase	NN	B-NP
O	106	107	I	I	CD	I-NP
O	108	109	(	(	(	O
O	109	113	topo	topo	NN	B-NP
O	114	115	I	I	CD	I-NP
O	115	116	)	)	)	O
O	117	119	is	be	VBZ	B-VP
O	120	122	an	an	DT	B-NP
O	123	132	important	important	JJ	I-NP
O	133	139	target	target	NN	I-NP
O	140	143	for	for	IN	B-PP
O	144	147	the	the	DT	B-NP
O	148	157	treatment	treatment	NN	I-NP
O	158	160	of	of	IN	B-PP
B-Cancer	161	170	malignant	malignant	JJ	B-NP
I-Cancer	171	178	disease	disease	NN	I-NP
O	178	179	,	,	,	O
O	180	190	especially	especially	RB	B-NP
B-Cancer	191	201	colorectal	colorectal	JJ	I-NP
I-Cancer	202	208	cancer	cancer	NN	I-NP
O	208	209	.	.	.	O

O	210	217	Because	Because	IN	B-SBAR
O	218	223	there	there	EX	B-NP
O	224	226	is	be	VBZ	B-VP
O	227	233	little	little	JJ	B-NP
O	234	245	information	information	NN	I-NP
O	246	248	on	on	IN	B-PP
O	249	252	the	the	DT	B-NP
O	253	263	expression	expression	NN	I-NP
O	264	266	of	of	IN	B-PP
O	267	271	topo	topo	NN	B-NP
O	272	273	I	I	CD	I-NP
O	274	276	in	in	IN	B-PP
B-Cancer	277	287	colorectal	colorectal	JJ	B-NP
I-Cancer	288	294	tumors	tumor	NNS	I-NP
O	294	295	,	,	,	O
O	296	300	this	this	DT	B-NP
O	301	306	study	study	NN	I-NP
O	307	316	evaluated	evaluate	VBD	B-VP
O	317	320	and	and	CC	I-VP
O	321	334	characterized	characterize	VBD	I-VP
O	335	339	topo	topo	NN	B-NP
O	340	341	I	I	NN	I-NP
O	342	349	protein	protein	NN	I-NP
O	350	360	expression	expression	NN	I-NP
O	361	363	in	in	IN	B-PP
B-Cancer	364	371	primary	primary	JJ	B-NP
I-Cancer	372	382	colorectal	colorectal	JJ	I-NP
I-Cancer	383	389	cancer	cancer	NN	I-NP
O	390	393	and	and	CC	I-NP
B-Cancer	394	399	lymph	lymph	NN	I-NP
I-Cancer	400	404	node	node	NN	I-NP
I-Cancer	405	415	metastases	metastasis	NNS	I-NP
O	416	419	and	and	CC	O
O	420	427	studied	study	VBD	B-VP
O	428	431	the	the	DT	B-NP
O	432	443	association	association	NN	I-NP
O	444	451	between	between	IN	B-PP
O	452	456	topo	topo	NN	B-NP
O	457	458	I	I	CD	I-NP
O	459	466	protein	protein	NN	I-NP
O	467	477	expression	expression	NN	I-NP
O	478	481	and	and	CC	O
O	482	499	clinicopathologic	clinicopathologic	JJ	B-NP
O	500	504	data	datum	NNS	I-NP
O	504	505	,	,	,	O
O	506	509	p53	p53	NN	B-NP
O	510	516	status	status	NN	I-NP
O	516	517	,	,	,	O
O	518	521	and	and	CC	O
O	522	535	proliferating	proliferate	VBG	B-VP
O	536	540	cell	cell	NN	B-NP
O	541	548	nuclear	nuclear	JJ	I-NP
O	549	556	antigen	antigen	NN	I-NP
O	557	558	(	(	(	O
O	558	562	PCNA	PCNA	NN	B-NP
O	562	563	)	)	)	O
O	564	570	status	status	NN	B-NP
O	570	571	.	.	.	O

O	572	592	Immunohistochemistry	Immunohistochemistry	NN	B-NP
O	593	598	assay	assay	NN	I-NP
O	599	602	was	be	VBD	B-VP
O	603	612	performed	perform	VBN	I-VP
O	613	616	for	for	IN	B-PP
O	617	621	topo	topo	NN	B-NP
O	622	623	I	I	CD	I-NP
O	624	631	protein	protein	NN	I-NP
O	632	642	expression	expression	NN	I-NP
O	643	645	in	in	IN	B-PP
O	646	649	249	249	CD	B-NP
B-Cancer	650	657	primary	primary	JJ	I-NP
I-Cancer	658	663	human	human	JJ	I-NP
I-Cancer	664	674	colorectal	colorectal	JJ	I-NP
I-Cancer	675	681	cancer	cancer	NN	I-NP
O	682	685	and	and	CC	O
O	686	688	42	42	CD	B-NP
O	689	695	paired	paired	JJ	I-NP
B-Cancer	696	701	lymph	lymph	NN	I-NP
I-Cancer	702	706	node	node	NN	I-NP
I-Cancer	707	717	metastasis	metastasis	NN	I-NP
I-Cancer	718	725	samples	sample	NNS	I-NP
O	725	726	.	.	.	O

O	727	731	Topo	Topo	RB	B-NP
O	732	733	I	I	CD	I-NP
O	734	744	expression	expression	NN	I-NP
O	745	748	was	be	VBD	B-VP
O	749	758	described	describe	VBN	I-VP
O	759	761	as	as	IN	B-PP
O	762	765	the	the	DT	B-NP
O	766	776	percentage	percentage	NN	I-NP
O	777	779	of	of	IN	B-PP
B-Cell	780	785	cells	cell	NNS	B-NP
O	786	794	staining	stain	VBG	B-VP
O	795	803	positive	positive	JJ	B-ADJP
O	804	807	for	for	IN	B-PP
O	808	812	topo	topo	NN	B-NP
O	813	814	I	I	CD	I-NP
O	814	815	,	,	,	O
O	816	821	along	along	IN	B-PP
O	822	826	with	with	IN	B-PP
O	827	830	the	the	DT	B-NP
O	831	840	intensity	intensity	NN	I-NP
O	841	844	and	and	CC	I-NP
O	845	857	localization	localization	NN	I-NP
O	858	860	of	of	IN	B-PP
O	861	864	the	the	DT	B-NP
O	865	873	staining	staining	NN	I-NP
O	873	874	.	.	.	O

O	875	892	Clinicopathologic	Clinicopathologic	JJ	B-NP
O	893	897	data	datum	NNS	I-NP
O	898	899	(	(	(	O
O	899	902	sex	sex	NN	B-NP
O	902	903	,	,	,	O
O	904	907	age	age	NN	B-NP
O	907	908	,	,	,	O
O	909	914	Dukes	Dukes	NNP	B-NP
O	914	915	'	'	POS	B-NP
O	916	921	stage	stage	NN	I-NP
O	921	922	,	,	,	O
O	923	938	differentiation	differentiation	NN	B-NP
O	939	944	grade	grade	NN	I-NP
O	944	945	,	,	,	O
O	946	954	survival	survival	NN	B-NP
O	955	961	status	status	NN	I-NP
O	961	962	)	)	)	O
O	962	963	,	,	,	O
O	964	967	p53	p53	NN	B-NP
O	968	974	status	status	NN	I-NP
O	974	975	,	,	,	O
O	976	979	and	and	CC	O
O	980	984	PCNA	PCNA	NN	B-NP
O	985	991	status	status	NN	I-NP
O	992	996	were	be	VBD	B-VP
O	997	1010	statistically	statistically	RB	I-VP
O	1011	1019	analyzed	analyze	VBN	I-VP
O	1020	1023	for	for	IN	B-PP
O	1024	1035	association	association	NN	B-NP
O	1036	1040	with	with	IN	B-PP
O	1041	1045	topo	topo	NN	B-NP
O	1046	1047	I	I	CD	I-NP
O	1048	1055	protein	protein	NN	I-NP
O	1056	1066	expression	expression	NN	I-NP
O	1066	1067	.	.	.	O

O	1068	1072	Topo	Topo	RB	B-NP
O	1073	1074	I	I	CD	I-NP
O	1075	1085	expression	expression	NN	I-NP
O	1086	1088	in	in	IN	B-PP
O	1089	1095	paired	paired	JJ	B-NP
B-Cancer	1096	1103	primary	primary	JJ	I-NP
I-Cancer	1104	1109	lymph	lymph	NN	I-NP
I-Cancer	1110	1114	node	node	NN	I-NP
I-Cancer	1115	1125	metastases	metastasis	NNS	I-NP
O	1126	1130	were	be	VBD	B-VP
O	1131	1138	studied	study	VBN	I-VP
O	1139	1142	for	for	IN	B-PP
O	1143	1154	concordance	concordance	NN	B-NP
O	1154	1155	.	.	.	O

O	1156	1160	Topo	Topo	RB	B-NP
O	1161	1162	I	I	CD	I-NP
O	1163	1170	protein	protein	NN	I-NP
O	1171	1181	expression	expression	NN	I-NP
O	1182	1185	was	be	VBD	B-VP
O	1186	1194	detected	detect	VBN	I-VP
O	1195	1197	in	in	IN	B-PP
O	1198	1201	127	127	CD	B-NP
O	1202	1203	(	(	(	O
O	1203	1205	51	51	CD	B-NP
O	1205	1206	%	%	NN	I-NP
O	1206	1207	)	)	)	O
B-Cancer	1208	1215	samples	sample	NNS	B-NP
O	1215	1216	,	,	,	O
O	1217	1226	including	include	VBG	B-PP
O	1227	1229	24	24	CD	B-NP
O	1229	1230	.	.	.	O
O	1230	1231	4	4	CD	B-NP
O	1231	1232	%	%	NN	I-NP
O	1233	1237	with	with	IN	B-PP
O	1238	1239	>	>	JJR	B-NP
O	1239	1241	50	50	CD	I-NP
O	1241	1242	%	%	NN	I-NP
O	1243	1251	positive	positive	JJ	I-NP
B-Cell	1252	1257	tumor	tumor	NN	I-NP
I-Cell	1258	1263	cells	cell	NNS	I-NP
O	1263	1264	.	.	.	O

O	1265	1268	The	The	DT	B-NP
O	1269	1277	majority	majority	NN	I-NP
O	1278	1281	had	have	VBD	B-VP
B-Cellular_component	1282	1289	nuclear	nuclear	JJ	B-ADJP
O	1290	1291	(	(	(	O
O	1291	1293	70	70	CD	B-NP
O	1293	1294	.	.	.	O
O	1294	1295	1	1	CD	B-NP
O	1295	1296	%	%	NN	I-NP
O	1296	1297	)	)	)	O
O	1298	1300	or	or	CC	O
B-Cellular_component	1301	1308	nuclear	nuclear	JJ	B-NP
O	1309	1312	and	and	CC	I-NP
B-Organism_substance	1313	1324	cytoplasmic	cytoplasmic	JJ	I-NP
O	1325	1333	staining	staining	NN	I-NP
O	1334	1335	(	(	(	O
O	1335	1337	17	17	CD	B-NP
O	1337	1338	.	.	.	O
O	1338	1339	3	3	CD	B-NP
O	1339	1340	%	%	NN	I-NP
O	1340	1341	)	)	)	O
O	1341	1342	.	.	.	O

O	1343	1344	A	A	DT	B-NP
O	1345	1351	higher	high	JJR	I-NP
O	1352	1362	percentage	percentage	NN	I-NP
O	1363	1365	of	of	IN	B-PP
B-Cell	1366	1371	cells	cell	NNS	B-NP
O	1372	1382	expressing	express	VBG	B-VP
O	1383	1387	topo	topo	NN	B-NP
O	1388	1389	I	I	CD	I-NP
O	1390	1392	in	in	IN	B-PP
B-Cancer	1393	1400	primary	primary	JJ	B-NP
I-Cancer	1401	1411	colorectal	colorectal	JJ	I-NP
I-Cancer	1412	1418	cancer	cancer	NN	I-NP
O	1419	1422	was	be	VBD	B-VP
O	1423	1436	significantly	significantly	RB	I-VP
O	1437	1447	associated	associate	VBN	I-VP
O	1448	1452	with	with	IN	B-PP
O	1453	1461	advanced	advance	VBN	B-NP
O	1462	1465	age	age	NN	I-NP
O	1466	1467	(	(	(	O
O	1467	1468	P	P	NN	B-NP
O	1469	1470	=	=	SYM	B-VP
O	1470	1471	.	.	.	B-NP
O	1471	1474	040	040	CD	I-NP
O	1474	1475	)	)	)	O
O	1475	1476	.	.	.	O

O	1477	1485	Patients	Patient	NNS	B-NP
O	1486	1490	with	with	IN	B-PP
B-Cancer	1491	1497	rectal	rectal	JJ	B-NP
I-Cancer	1498	1504	cancer	cancer	NN	I-NP
O	1505	1508	had	have	VBD	B-VP
O	1509	1516	greater	great	JJR	B-NP
O	1517	1521	topo	topo	NN	I-NP
O	1522	1523	I	I	CD	I-NP
O	1524	1534	expression	expression	NN	I-NP
O	1535	1539	than	than	IN	B-PP
O	1540	1545	those	those	DT	B-NP
O	1546	1550	with	with	IN	B-PP
B-Cancer	1551	1556	colon	colon	NN	B-NP
I-Cancer	1557	1563	tumors	tumor	NNS	I-NP
O	1564	1565	(	(	(	O
O	1565	1566	P	P	NN	B-NP
O	1567	1568	=	=	SYM	B-VP
O	1568	1569	.	.	.	B-NP
O	1569	1572	029	029	CD	I-NP
O	1572	1573	)	)	)	O
O	1573	1574	.	.	.	O

O	1575	1577	No	No	DT	B-NP
O	1578	1589	significant	significant	JJ	I-NP
O	1590	1601	correlation	correlation	NN	I-NP
O	1602	1605	was	be	VBD	B-VP
O	1606	1611	found	find	VBN	I-VP
O	1612	1619	between	between	IN	B-PP
O	1620	1624	topo	topo	NN	B-NP
O	1625	1626	I	I	CD	I-NP
O	1627	1634	protein	protein	NN	I-NP
O	1635	1645	expression	expression	NN	I-NP
O	1646	1649	and	and	CC	O
O	1650	1653	sex	sex	NN	B-NP
O	1653	1654	,	,	,	O
O	1655	1660	Dukes	Dukes	NNP	B-NP
O	1660	1661	'	'	POS	B-NP
O	1662	1667	stage	stage	NN	I-NP
O	1667	1668	,	,	,	O
O	1669	1684	differentiation	differentiation	NN	B-NP
O	1685	1690	grade	grade	NN	I-NP
O	1690	1691	,	,	,	O
O	1692	1700	survival	survival	NN	B-NP
O	1701	1707	status	status	NN	I-NP
O	1707	1708	,	,	,	O
O	1709	1712	p53	p53	NN	B-NP
O	1713	1719	status	status	NN	I-NP
O	1719	1720	,	,	,	O
O	1721	1724	and	and	CC	O
O	1725	1729	PCNA	PCNA	NN	B-NP
O	1730	1736	status	status	NN	I-NP
O	1736	1737	.	.	.	O

O	1738	1749	Concordance	Concordance	NN	B-NP
O	1750	1752	in	in	IN	B-PP
O	1753	1757	topo	topo	NN	B-NP
O	1758	1759	I	I	CD	I-NP
O	1760	1768	staining	staining	NN	I-NP
O	1769	1776	between	between	IN	B-PP
B-Cancer	1777	1784	primary	primary	JJ	B-NP
O	1785	1788	and	and	CC	I-NP
B-Cancer	1789	1794	lymph	lymph	NN	I-NP
I-Cancer	1795	1799	node	node	NN	I-NP
I-Cancer	1800	1810	metastases	metastasis	NNS	I-NP
O	1811	1814	was	be	VBD	B-VP
O	1815	1823	observed	observe	VBN	I-VP
O	1824	1826	in	in	IN	B-PP
O	1827	1829	33	33	CD	B-NP
O	1830	1832	of	of	IN	B-PP
O	1833	1835	42	42	CD	B-NP
O	1836	1841	cases	case	NNS	I-NP
O	1842	1843	(	(	(	O
O	1843	1844	P	P	NN	B-NP
O	1845	1846	=	=	SYM	B-VP
O	1846	1847	.	.	.	B-NP
O	1847	1850	029	029	CD	I-NP
O	1850	1851	)	)	)	O
O	1851	1852	.	.	.	O

O	1853	1857	This	This	DT	B-NP
O	1858	1866	suggests	suggest	VBZ	B-VP
O	1867	1871	that	that	IN	B-SBAR
O	1872	1875	the	the	DT	B-NP
O	1876	1884	activity	activity	NN	I-NP
O	1885	1887	of	of	IN	B-PP
O	1888	1892	topo	topo	NN	B-NP
O	1893	1894	I	I	CD	B-NP
O	1895	1905	inhibitors	inhibitor	NNS	I-NP
O	1906	1910	will	will	MD	B-VP
O	1911	1914	not	not	RB	I-VP
O	1915	1921	differ	differ	VB	I-VP
O	1922	1928	across	across	IN	B-PP
O	1929	1936	various	various	JJ	B-NP
B-Cancer	1937	1942	tumor	tumor	NN	I-NP
O	1943	1949	stages	stage	NNS	I-NP
O	1949	1950	,	,	,	O
O	1951	1960	pathology	pathology	NN	B-NP
O	1960	1961	,	,	,	O
O	1962	1965	and	and	CC	O
O	1966	1973	patient	patient	NN	B-NP
O	1974	1980	gender	gender	NN	I-NP
O	1980	1981	.	.	.	O

O	1982	1985	p53	p53	NN	B-NP
O	1986	1989	and	and	CC	I-NP
O	1990	1994	PCNA	PCNA	NN	I-NP
O	1995	2001	status	status	NN	I-NP
O	2002	2004	do	do	VBP	B-VP
O	2005	2008	not	not	RB	I-VP
O	2009	2015	appear	appear	VB	I-VP
O	2016	2018	to	to	TO	I-VP
O	2019	2028	influence	influence	VB	I-VP
O	2029	2033	topo	topo	NN	B-NP
O	2034	2035	I	I	NN	I-NP
O	2036	2046	expression	expression	NN	I-NP
O	2046	2047	,	,	,	O
O	2048	2051	and	and	CC	O
O	2052	2056	topo	topo	NN	B-NP
O	2057	2058	I	I	PRP	B-NP
O	2059	2062	has	have	VBZ	B-VP
O	2063	2065	no	no	DT	B-NP
O	2066	2074	apparent	apparent	JJ	I-NP
O	2075	2086	association	association	NN	I-NP
O	2087	2091	with	with	IN	B-PP
O	2092	2095	the	the	DT	B-NP
O	2096	2107	acquisition	acquisition	NN	I-NP
O	2108	2110	of	of	IN	B-PP
O	2111	2112	a	a	DT	B-NP
O	2113	2123	metastatic	metastatic	JJ	I-NP
O	2124	2133	phenotype	phenotype	NN	I-NP
O	2133	2134	.	.	.	O

O	2135	2139	Topo	Topo	RB	B-NP
O	2140	2141	I	I	CD	I-NP
O	2142	2152	expression	expression	NN	I-NP
O	2153	2156	now	now	RB	B-ADVP
O	2157	2162	needs	need	VBZ	B-VP
O	2163	2165	to	to	TO	I-VP
O	2166	2168	be	be	VB	I-VP
O	2169	2178	evaluated	evaluate	VBN	I-VP
O	2179	2181	in	in	IN	B-PP
O	2182	2190	patients	patient	NNS	B-NP
O	2191	2201	undergoing	undergo	VBG	B-VP
O	2202	2206	topo	topo	NN	B-NP
O	2207	2208	I	I	CD	I-NP
O	2208	2209	-	-	HYPH	I-NP
O	2209	2218	inhibitor	inhibitor	NN	I-NP
O	2219	2226	therapy	therapy	NN	I-NP
O	2226	2227	,	,	,	O
O	2228	2230	to	to	TO	B-VP
O	2231	2237	better	well	RBR	I-VP
O	2238	2244	define	define	VB	I-VP
O	2245	2248	the	the	DT	B-NP
O	2249	2253	role	role	NN	I-NP
O	2254	2256	of	of	IN	B-PP
O	2257	2261	this	this	DT	B-NP
O	2262	2269	protein	protein	NN	I-NP
O	2270	2272	as	as	IN	B-PP
O	2273	2274	a	a	DT	B-NP
O	2275	2285	predictive	predictive	JJ	I-NP
O	2286	2292	marker	marker	NN	I-NP
O	2292	2293	.	.	.	O

